Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 114,022

Document Document Title
WO/2019/006951A1
The invention relates to an application of a dipeptide for preparing antihypertensive drug or health care product. Virtual screening has been performed on a dipeptide based on ACE inhibitory effects according to a previously detected ACE...  
WO/2019/007418A1
The present invention relates to the technical field of pharmacy, and specifically relates to a compound as represented by formula (I), and a pharmaceutically acceptable salt, an ester or stereoisomers thereof. R1, X1, X2, M, Ar, ring A,...  
WO/2019/010301A1
The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAPβ, o...  
WO/2019/008438A1
The disclosure relates to modified apelin polypeptides having increased stability against kaliikrein, NEP and ACE2 degradation and/or potency relative to the native apelin-13 and apelin-17 polypeptides. Embodiments also disclose methods ...  
WO/2019/010464A1
The present invention provides compositions and methods for improving cardiac function. Specifically, the present invention provides compositions and methods for treating a subject having a disorder or condition associated with aberrant ...  
WO/2019/006955A1
The invention relates to an application of acid amide dipeptide for preparing antihypertensive drug or health care product. Virtual screening has been performed on a dipeptide based on ACE inhibitory effects according to a previously det...  
WO/2019/006953A1
Disclosed is the use of a non-ionized polar dipeptide in the preparation of antihypertensive drugs or healthcare products. According to the crystal structure of a determined ACE enzyme, virtual screening for the ACE inhibition of the dip...  
WO/2019/009355A1
The present invention provides: an assay method that uses a compound represented by formula (I) as a fluorescent probe molecule and that is for detecting the lipid peroxidation suppression activity of a test compound; an assay kit that u...  
WO/2019/008077A1
A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) t...  
WO/2019/007072A1
Disclosed is the use of a dipeptide YY in the preparation of a drug or healthcare product for lowering blood pressure. According to the crystal structure of the enzyme ACE, which structure is already determined, the present invention use...  
WO/2019/006512A1
Activation of β-catenin in cardiomyocytes enhances or stimulates cardiomyocyte regeneration to thereby prevent or treat diseases or conditions of the heart such as ischaemic heart disease. One or more other genetic elements such as Yes-...  
WO/2019/007015A1
The present invention provides application of a compound of a thioether acid structure in preparing drugs for treating or preventing cardiovascular and cerebrovascular diseases caused by platelet aggregation. Carbocisteine, fudosteine, e...  
WO/2019/008025A1
The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylure...  
WO/2019/006952A1
The invention relates to the application of a cyclic nonpolar dipeptide for preparing an antihypertensive drug or a health care product. Virtual screening has been performed on a dipeptide based on ACE inhibitory effects according to a p...  
WO/2019/006956A1
The invention relates to an application of a basic dipeptide for preparing an antihypertensive drug or a health care product. Virtual screening has been performed on a dipeptide based on ACE inhibitory effects according to a previously d...  
WO/2019/006954A1
The invention relates to an application of sulfur dipeptide for preparing an antihypertensive drug or a health care product. Virtual screening has been performed on a dipeptide based on ACE inhibitory effects according to a previously de...  
WO/2019/006690A1
Provided are a polypeptide pharmaceutically acceptable salt and a pharmaceutical composition thereof, said polypeptide containing an amino acid sequence YEKLLDTEI or functional variants thereof.  
WO/2019/010352A1
The present invention includes composition and methods for inhibiting or decreasing impaired systolic ejection fraction associated with cardiotoxic therapeutic treatment in a subject receiving a cardiotoxic chemotherapeutic agent causing...  
WO/2019/001307A1
An amide compound of formula (I), a polymorph, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, an isotope variant, a hydrate, or a solvate thereof, a pharmaceutical composition containing the compound, and a pharmaceutical...  
WO/2019/004808A1
The present invention concerns medicine, and describes a novel application of PRS in the treatment of autonomic dysregulations of the vagal dysfunction type, and more specifically symptomatic dysautonomic tachycardia following severe vag...  
WO/2019/004155A1
Provided is a tablet which is highly resistant against impact and abrasion and in which defects in a cup portion and an edge can be effectively avoided. A tablet 1 which comprises a cup portion 12 formed on the upper and/or lower sides o...  
WO/2019/005685A1
A method for treating a neurodegenerative disease or an inflammatory disorder in a subject, comprising administering to the subject in need thereof, a compound, or a pharmaceutically acceptable salt thereof, of formula II: wherein each o...  
WO/2019/003433A1
The present invention provides: a novel benzazepine compound which is represented by formula (1) and has vasopressin V1a and V2 antagonism, or a salt thereof; and a pharmaceutical use thereof. [In formula, R1 represents optionally substi...  
WO/2019/001416A1
The present invention provides a thiazolinone heterocyclic compound and a preparation method, pharmaceutical composition, and application thereof. The present invention provides an application of the thiazolinone heterocyclic compound in...  
WO/2019/000504A1
Provided are a PDE 5 and a preparation method therefor, and application of the PDE 5 to preparation of drugs used for treating, alleviating or preventing PDE 5-related diseases or disease states of mammals. The structural formula of the ...  
WO/2019/006235A1
Provided herein are methods of treating a subject with heart failure, comprising administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, and subsequently administering to the subjec...  
WO/2019/004466A1
Provided is a medicine for safely treating a patient who needs to be treated with the use of pemafibrate, a salt thereof or a solvate of the same (hereinafter called "pemafibrate treatment"). The medicine for treating a patient who needs...  
WO/2019/004465A1
Provided is a method for treating patients with cirrhosis by appropriately using pemafibrate. The present invention pertains to usage of pemafibrate for patients with cirrhosis. Specifically, the present invention pertains to a dosage re...  
WO/2018/232805A1
Provided are a puerarin derivative represented by formula (I) or formula (II) or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a use thereof for the prevention and treatment of cardiovascular and cerebrov...  
WO/2018/235785A1
The present invention relates to a compound set forth as an example compound or a pharmaceutically acceptable salt of the compound.  
WO/2018/234565A1
The present invention is directed to the use of cangrelor for the treatment and/or prevention of shunt thrombosis in patients suffering congenital heart diseases undergoing shunt surgery.The invention is also directed to the use of cangr...  
WO/2018/234861A1
The present invention concerns the use of plasminogen, a variant thereof, or an analog thereof having a plasminogen activity, for the prevention or treatment of a condition or a disease that is characterized with an increased PAI-1 level...  
WO/2018/233604A1
Provided are an application of a plasminogen to regulate and control the GLP-1/GLP-1R and the treatment of GLP-1/GLP-1R related diseases.  
WO/2018/232884A1
Disclosed are a composition having the effects of lowering both blood pressure and blood sugar and a preparation method thereof. The composition is prepared from a solid culture of Phellinus linteus, Siraitia grosvenori and water. The co...  
WO/2018/236909A1
Novel engineered T-cell receptors including modified TCRs and CARs targeting athero-relevant antigen-MHCs are disclosed. Also provided are novel methods for treating diseases or conditions related to inflammation and atherosclerosis.  
WO/2018/237243A1
Disclosed is the use of garcinol for the therapeutic management of ER stress. More specifically, the invention discloses the ability of garcinol in decreasing ER stress and mitigating toxicity by reducing protein aggregation and decreasi...  
WO/2018/233553A1
Disclosed are a fused bicyclic compound and the use thereof in a medicine, particularly a novel fused bicyclic compound used as an ASK1 activity regulator and a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a...  
WO/2018/237394A1
The non-natural enantiomer (ent-(+)-verticilide) and uses for treatment of RyR2-mediated spontaneous Ca2+ leak, arrhythmia and memory loss.  
WO/2018/228616A1
A composite mixture for the treatment or the treatment support of neurodegenerative, vascular, inflammatory, metabolic, and immunological diseases wherein it comprises from 0.1 to 25% by weight of extract from cannabis sativa plant and/o...  
WO/2018/227809A1
The present invention relates to a traditional Chinese medicine for treating hypotension dizziness, prepared from the following raw herbs in parts by weight: Radix Codonopsis: 6; Rhizoma Cimicifugae: 10; Fructus Aurantii: 10; Radix Buple...  
WO/2018/229785A1
The invention relates to oral pharmaceutical compositions comprising Ticagrelor and pharmaceutically acceptable polymer in a ratio of 1:0.1 to 1:1 in the form of solid dispersion and process for the preparation of such compositions.  
WO/2018/229630A1
The present invention is directed to methods for reducing, preventing or slowing the progression of cardiovascular risk factors and / or cardiovascular disease, comprising administration of canagliflozin.  
WO/2018/231092A1
The invention relates to the field of pharmaceutics and cosmetology. The cosmeticological and pharmaceutical composition comprises the quercetin derivative in the form of a supramolecular mixture of modified combinatorial quercetin deriv...  
WO/2018/231702A1
Provided are methods for improving the efficacy and success of cell-based therapies by administration of stem cells which have been preconditioned with an inhibitor of soluble epoxide hydrolase (sEHI), as well as kits, stents and patches...  
WO/2018/229461A1
A method of treating and/or preventing aortic stenosis in a patient in need thereof comprises administering to the patient a therapeutically effective amount of sevelamer or a pharmaceutically acceptable derivative, mixture or salt there...  
WO/2018/227427A1
The present application relates to novel imidazopyridinyl-or imidazopyrimidinyl-substituted, bridged 1,4-diazepane derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention...  
WO/2018/224869A1
The present invention relates to a composition comprising: astaxanthin, piperine, boswellic acids, coenzyme Q10, curcuminoids, lutein, zeaxanthin, saffron, copper and, optionally, resveratrol, bromelain, zinc, salicin and further antioxi...  
WO/2018/223909A1
Provided is a chimeric molecule consisting of a small molecule compound unit of a target protein, an E3 ubiquitin ligase binding unit and a linkage unit. The chimeric molecule can bind to a BRD protein, enable the BRD protein to be more ...  
WO/2018/225673A1
Disclosed are: a method for manufacturing a therapeutic composition containing mammalian cells, said method comprising dispersing the mammalian cells in an aqueous glucose solution having a concentration of about 3-10% or Ringer's acetat...  
WO/2018/226833A1
The present invention provides methods of suppressing the activation of microglial cells, methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral inflammation, methods of ameliorating or treating spe...  

Matches 1 - 50 out of 114,022